Action Biotech releases telatinib Stage 2 trial data for metastatic stomach cancer ACT Biotech.

‘We are hopeful that telatinib may present these patients an effective treatment which can be safely combined with chemotherapy without adding toxicity. We are on track to initiate Phase 3 clinical tests of telatinib for frontline treatment of abdomen cancer patients this season. Because of telatinib’s unique ability to effectively match multiple chemotherapy regimens at complete, continuous dosing, we are encouraged to develop telatinib in additional solid tumor indications, including colorectal, breast, and kidney cancers.’.. Action Biotech releases telatinib Stage 2 trial data for metastatic stomach cancer ACT Biotech, Inc., a biopharmaceutical company focused on the advancement of highly targeted, oral therapeutics for the treatment of malignancy, today released data on additional analysis of the Phase 2 scientific trial of telatinib in individuals with metastatic stomach cancer that further helps the highly-potent nature of the antiangiogenic agent.Beneath the conditions of the agreements, Fresenius and APP Kabi are granted a permit to advertise their generic versions of oxaliplatin, 50 mg/vial, 100 mg/vial and 5mg/mL, 10 mL and 20 mL vials, beginning no later than August 9, 2012. Regarding to IMS data, U.S.

Abbott RealTime HCV Genotype II assay receives FDA approval FDA approves first genotyping check for individuals with hepatitis C virus The U.S. Food and Medication Administration today approved a test that identifies the genotype of hepatitis C virus a patient is carrying. The Abbott RealTime HCV Genotype II, that may differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5,utilizing a sample of an contaminated patient's blood serum or plasma, will aid health care professionals in determining the correct approach to treatment.